AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

Citi analyst Geoff Meacham maintained a Hold rating on AbbVie (ABBV – Research Report) today. The company’s shares closed last Wednesday at $185.49. Confident Investing Starts ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.